Maintenance Therapy for Newly Diagnosed Ovarian Cancer: PARP Inhibitors, Bevacizumab, or Both? (or Perhaps Neither)

This online course is a highlight from the 2021 live virtual symposium which was hosted by the Miami Cancer Institute. The symposium brought together a distinguished faculty to focus on the medical management of common and important challenges facing healthcare professionals who care for women with cancer.

Learn more about the Womens’ Cancer Symposium here.

In Maintenance Therapy for Newly Diagnosed Ovarian Cancer, Dr. Jason Konner of Memorial Sloan Kettering reviews the options of maintenance therapy for ovarian cancer patients. He examines the therapies and their impact on disease progression. 

Target Audience

Breast Surgeons, General Surgeons, Reconstructive Surgeons, Obstetricians and Gynecologists, Oncologists, Physiatrist, Radiation Oncologists, Pathologists, Geneticists, Radiologists, General Practitioners and all other interested healthcare professionals.

Learning Objectives

  • Identify FDA-approved options for first-line post-remission therapy for ovarian cancer.
  • Understand the rationale and data that underlie these treatments.
  • Learn strategies for making therapeutic choices for individual patients.
Additional information
Bibliography: 
  • Moore, K., Colombo, N., Scambia, G., Kim, B. G., Oaknin, A., Friedlander, M., ... & DiSilvestro, P. (2018). Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine, 379(26), 2495-2505.
  • Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., ... & Harter, P. (2019). Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England Journal of Medicine, 381(25), 2416-2428.
  • Martín, A. G., Pothuri, B., Vergote, I. B., Christensen, R. D., Graybill, W., Mirza, M. R., ... & Monk, B. J. (2019). Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study). Annals of Oncology, 30, v893.
  • Morice, P. M., Leary, A., Dolladille, C., Chrétien, B., Poulain, L., González-Martín, A., ... & Alexandre, J. (2020). Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. The Lancet Haematology, 8(2), e122–e134.

Related Topics

Miami Cancer Institute Online Series (Multiple Modules)
This online educational series features Miami Cancer Institute (MCI) physician experts and national subject matter experts who have presented at our recent symposiums. Topics highlight the latest advances in cancer imaging, chemotherapy, surgical interventions, radiotherapy and proton therapy. Visit us often, as this catalog will be updated frequently.
Course Summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 General certificate of attendance
Course opens: 
07/01/2021
Course expires: 
06/30/2022

Jason A. Konner, M.D.
Director, GMO New Jersey
Gynecologic Medical Oncology & Early Drug Development 
Clinical Member, Memorial Hospital
Memorial Sloan Kettering Cancer Center
New York, New York 

Jason A. Konner, M.D., faculty for this educational activity, has indicated that he is a consultant with Clovis, Astra Zeneca and Merck. He has received research funding from Immunogen, Inc. His presentation will not include discussion of off-label or unapproved usage.

Symposium Directors:
John P. Diaz, M.D., has indicated that he is a member of the speakers’ bureau for AstraZeneca and Merck. 

Gladys L. Giron, M.D., has indicated that her spouse is a consultant for Stryker. 

Nicholas C. Lambrou, M.D., has indicated that he is a consultant for Intuitive, Ethicon and Johnson & Johnson. 

Starr K. Mautner, M.D., has indicated that she does not have any relevant relationships with ineligible companies* to disclose. 

All of the relevant financial relationships listed for these individuals have been mitigated.

Other individuals involved in planning, content review, approval, or moderating for this educational activity have no relevant financial relationships to disclose with ineligible companies*. 

*Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
              
Baptist Health South Florida designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 General certificate of attendance
Please login or register for a Baptist Health CME account to take this course.

Required Hardware/Software

PC/Mac Users
PC/Mac Users

This site is supported on the most recent stable releases of the following browsers:

Click Here to Download Google Chrome
Google Chrome		Microsoft Edge
Microsoft Edge		Safari
Safari		Moxilla Firefox
Mozilla Firefox
Internet Explorer

Attention: Internet Explorer Users
This site offers limited support for Internet Explorer 11 (IE11). When using IE11, you will be prompted to download course videos instead of viewing them in the browser. After the course video downloads, the recordings will play.

Mobile Users
Mobile Users

This site is supported on the following mobile devices:

  • Apple iOS mobile devices running iOS 10 or later
  • Android mobile devices running Android 4.4 or later, with the latest release of Google Chrome or Mozilla Firefox
Technical Support
Technical Support

If you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.